Interesting Science Stuff

UAH

All-American
Nov 27, 2017
4,092
5,175
187
In Cleveland, mushrooms digest entire houses: How fungi can be used to clean up pollution
BBC

Interesting article on dealing with hazardous waste such as lead paint and other hazardous waste in old houses. Let fungus handle solid waste disposal.
 
  • Thank You
Reactions: NationalTitles18

NationalTitles18

TideFans Legend
May 25, 2003
32,414
42,254
362
Mountainous Northern California

GLP-1 agonists for Parkinson's?

Wow.

GLP-1 Drugs for Parkinson’s Disease


It’s important to first point out that there are no disease-modifying interventions for Parkinson’s disease. All current treatments are for symptoms but nothing has yet been validated to stop or slow progression of the disease. In the New England Journal of Medicine a double-blind randomized trial of 156 participants with early Parkinson’s disease were assigned to lixisenatide or placebo. Lixisentaide is a GLP-1 drug that was approved in the United States in 2016 and discontinued by its manufacturer (Sanofi) in 2023. The drug or matching placebo were given for 12 months and the primary endpoint, as shown below, was a motor score used by neurologists (Movement Disorder Scale-Unified Parkinson’s Disease Rating Scale) MDS-UPDRS Part III). The GLP-1 drug participants had no progression of motor symptoms (-0.04), and the 3.04 worsening in the placebo group (difference between the two arms=3.08) is just short of what is considered clinically meaningful (3.5).



This is not the first randomized trial reporting benefit of GLP-1 drugs for Parkinson’s. In 2013, a single-blind trial of 45 patients with exenatide showed significant statistical benefit but the motor score difference was 2.7 points.



In 2017, a small single-center randomized trial of 62 participants, but with longer follow-up, found benefit with exenatide given once weekly (see graph below). It concluded: "There is a strong indication that GLP-1 receptor agonists may have a useful role in future treatment of Parkinson's disease."



Of note, both trials had a washout period after the drug treatment ended and the benefit for motor symptoms persisted.

A key point made into accompanying editorial for the new trial is that the >3-point benefit may accrue further over time: “The importance of this finding is not the magnitude of the change but what it portends….if the benefit of lixisenatide is cumulative, adding another three points each year over a period of 5 to 10 years or more, then this could be a trill transformative treatment.”

There are 2 other important considerations. Lixisenatide and exenatide are much weaker GLP-1 drugs compared with semaglutide, tirzepatide and several others that are in clinical trials as shown below for weight loss. The extent of weight loss likely also reflects the potency of anti-inflammatory effect, and biomarkers indicative of reduced inflammation have been shown to precede wight loss in multiple trials of this drug class.



Also, we know that these drugs do not cross the blood brain barrier. As Daniel Drucker explained in the companion podcast, that isn’t necessary to achieve the GLP-1 mediated suppression of inflammation in the brain. There’s the gut-brain axis and enteric nervous system to relay signals, talk to the brain. As Drucker pointed out to me: “ We know that GLP-1 is not getting directly to those neurons, but it's activating pathways that turn on those neurons. And so, there's probably a very intricate set of pathways that sense the GLP-1 and the accessible neurons and then transmit those signals deeper into the brain.”

So the new study provides some optimism for Parkinson’s disease. The GLP-1 drug mediated suppression of brain inflammation may turn out to be yet another key use case. Note there are 2 large randomized trials of semaglutide for Alzheimer’s disease expected to report out in 2026.
 
  • Like
Reactions: rjtide and Toddrn

NationalTitles18

TideFans Legend
May 25, 2003
32,414
42,254
362
Mountainous Northern California
A bit more:

Summary


Pulling the new reports together, there is further momentum and excitement building for GLP-1 drug expanded use beyond diabetes and obesity. The treatment benefit for heart failure with preserved ejection fraction, accounting for more than half of heart failure cases, has now been replicated. The key finding of much less weight loss in the new trial with Type 2 diabetes helps us understand the story of GLP-1’s success— it’s not just because of reduced body weight. Especially of interest are the new findings in Parkinson’s disease. We desperately need an intervention that is disease-modifying and now there’s a chance we’ll get one. That will require a larger trial with longer duration of treatment—it deserves a high priority given the current results. With the effects seen of the GLP-1 family of drugs on preventing kidney damage in diabetes, liver disease (non-alcoholic or metabolic-associated steatosis, NASH/MASH), and addiction, this drug class is exceeding all expectations. Please consider taking time to listen to (or read the transcript) of the companion podcast with Daniel Drucker to get insights from his expertise, now >30 years of studying GLP-1 and related drugs.
 
  • Like
Reactions: dtgreg

Go Bama

Hall of Fame
Dec 6, 2009
14,816
16,640
187
16outa17essee
This is the best picture I got by holding the eclipse glasses over my iPhone. IMG_1908.jpeg
This was about as good as anyone did with an iPhone. You have to wear the eclipse glasses until everything goes completely dark. Then you take the glasses off, and this picture I downloaded from the web is much more accurate of what you see. Totality.jpg

The solar flares to the east and on the south pole were clearly visible. The dramatic effect it has when you first see it cannot be described.

This eclipse was to me better than the one in 2017, but both were amazing. I've never seen anything that had more of a WOW!!! effect.
 

Amazon Deals for TideFans!

YouTheFan Alabama Desk Pad

Purchases may result in a commission being paid to TideFans.

Latest threads